Novel perspectives in celiac disease therapy.
Currently the only treatment for celiac disease is adherence to a strict gluten-free diet; however, compliance with this diet is complex and other alternatives are called for. Herein, we review recent developments in the design of novel therapeutic strategies to counteract the pathogenic effects of the interactions between gluten peptides and their specific biological targets.
Sanz
Yolanda
Y
Microbial Ecophysiology and Nutrition Group. Institute of Agrochemistry and Food Technology (IATA), Spanish National Research Council (CSIC). PO Box 73, 46100 Burjassot, Valencia. Spain. yolsanz@iata.csic.es
D002446:Celiac Disease / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005983:Glutens / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010447:Peptide Hydrolases / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors
D015815:Cell Adhesion Molecules; D016207:Cytokines; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D011956:Receptors, Cell Surface; C402827:zonula occludens toxin receptor; D005983:Glutens; D010447:Peptide Hydrolases